Výsledky vyhledávání - "Tito Vanelli"

Akademický článek

Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma

Autor: Laura Fogliatto, Kamila Castro Grokoski, Yuri Machado Strey, Tito Vanelli, Christina Garcia da Silva Fraga, Marines Bizarro Barra, Fernanda Correa Pinto, Israel Bendit, Claúdia Giuliano Bica

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 41, Iss 1, Pp 50-56 (2019)

Background: Diffuse large B-cell lymphoma, among non-Hodgkin lymphomas, is one of the most frequent subtypes. Clinical laboratory data and post-treatment outcomes are scarce in the Brazilian population. Objective: The main objective of this retrospec

Externí odkaz: https://doaj.org/article/92a4beebc594480c8266bf82718ee785

Zobrazit plný text záznamu

What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?

Autor: Kamila Castro Grokoski, Christina G S Fraga, Guilherme Bosi, Liane Esteves Daudt, M. P. Pereira, Lucia Mariano da Rocha Silla, Tito Vanelli Costa, Marco Antônio Baptista Kalil, Nathan Bugs, Laura Fogliatto

Publikováno v: Hematology, Transfusion and Cell Therapy
Repositório Institucional da UFRGS
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
Hematology, Transfusion and Cell Therapy, Vol 41, Iss 3, Pp 222-228 (2019)

Objective: To assess clinical outcomes of intolerant, relapsed or refractory patients who could not be treated with new tyrosine kinase inhibitors or experimental therapies. Methods: A retrospective cohort of 90 chronic myeloid leukemia patients in a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b517f49a0261d6e051c23305e04d8716
https://pubmed.ncbi.nlm.nih.gov/31085148

Zobrazit plný text záznamu

Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome

Autor: Ceres Andréia Vieira de Oliveira, Giorgio Adriano Paskulin, Laura Fogliatto, Marcelo Capra, Tito Vanelli, Rafael Fabiano Machado Rosa, Paulo Ricardo Gazzola Zen, Dayane Bohn Koshiyama

Publikováno v: Annals of Hematology. 92:185-189

Variant Philadelphia (Ph) chromosome can be observed in 5-10 % of chronic myelogenous leukemia (CML) patients. However, there are only a few studies which have analyzed the prognostic implications of these complex translocations in CML patients after

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51227362358bd897cf9804955d6544d0
https://doi.org/10.1007/s00277-012-1598-8

Zobrazit plný text záznamu

DA-EPOCH Was Not Better Than CHOP for Acquired Immunodeficiency Syndrome-Related Diffuse Large B Cell Lymphoma Patients Treated in a South Brazilian University Hospital

Autor: Juliana Collman Silva, Paz Aparecida Alessandra, Tito Vanelli, Nicole Teixeira Carvalho, Jeziel Basso, Tatiana de Campos, Carolina F Gomes, Harold Fabian Ibanez Torres, Gueverson Rocha, Laura Fogliatto, Lucia Mariano da Rocha Silla

Publikováno v: Blood. 132:5414-5414

Introduction: Lymphomas are an important complication of HIV infection where they occur with high frequency and are a significant cause of morbidity and mortality.The most prevalent lymphoma subtype in HIV positive population is the diffuse large B c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a66a4b7962660c49ef05ef1e4d2e2bcf
https://doi.org/10.1182/blood-2018-99-117862

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacogenetic Markers of Treatment Response of Imatinib Mesylate in Chronic Myeloid Leukemia Brazilian Patients

Autor: Natalia Vieira, Fabiola Reginato, Vanessa Suñé Mattevi, Marcelo Capra, Pierre Wallemacq, Marina Venzon Antunes, Laura Fogliatto, Sandrine Comparsi Wagner, Renata Leite, Marília Remuzzi Zandoná, Tito Vanelli Costa, Rafael Linden, Arnaud Capron

Publikováno v: Blood. 128:5458-5458

The treatment of chronic myeloid leukemia (CML) was revolutionized by the introduction of imatinib mesylate (IM). However, approximately 20% of patients are non-responsive and interpatient variability in response to IM is still a phenomenon lacking e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c03300a7a22fa2fd8fd9e730091c4c9
https://doi.org/10.1182/blood.v128.22.5458.5458

Zobrazit plný text záznamu

Economic Impact of Imatinib Mesylate Withdraw: An Option for Third World Countries?

Autor: Liane Esteves Daudt, Mariana Monteiro Burin, Tito Vanelli, M. P. Pereira, Eduardo Gomes da Silva, Lucia Mariano da Rocha Silla, Tahiane de Brum Soares, Laura Fogliatto

Publikováno v: Blood. 126:5161-5161

Introduction: The advent of tyrosine kinase inhibitors has changed the natural history of chronic myelogenous leukemia (CML), promoting molecular remission in a high number of patients. In 40-60% of the patients that reach deep molecular responses (R

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::92bdae9fc093d9af79070a7bb0af7bef
https://doi.org/10.1182/blood.v126.23.5161.5161

Zobrazit plný text záznamu

BCR-ABL Fluctuation Analysis in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients with MR 4.5

Autor: Liane Esteves Daudt, André Dias Américo, Lucia Mariano da Rocha Silla, Mariana Monteiro Burin, M. P. Pereira, Laura Fogliatto, Tito Vanelli, Tahiane de Brum Soares, Eduardo Gomes da Silva

Publikováno v: Blood. 126:5162-5162

Introduction: Imatinibe, a target tyrosine kinase inhibitor, have revolutionized CP-CML treatment. Considering that it is being discussed imatinibe treatment interruption in patients with MR ≥ 4.5 lasting two years or more, we believe to be importa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b2f836bb48c625409236d9ea99440f4f
https://doi.org/10.1182/blood.v126.23.5162.5162

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání